Filing Details

Accession Number:
Form Type:
Zero Holdings:
Publication Time:
2020-11-18 19:43:50
Reporting Period:
Accepted Time:
2020-11-18 19:43:50
SEC Url:
Form 4 Filing
Cik Name Symbol Sector (SIC) IRS No
1743881 Bridgebio Pharma Inc. BBIO Pharmaceutical Preparations (2834) 000000000
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1779990 Thomas Michael Henderson C/o Bridgebio Pharma, Inc.
421 Kipling Street
Palo Alto CA 94301
Chief Business Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-11-16 10,000 $1.05 277,751 No 4 M Direct
Common Stock Disposition 2020-11-16 10,000 $45.00 267,751 No 4 S Direct
Common Stock Acquisiton 2020-11-16 12,813 $0.00 280,564 No 4 M Direct
Common Stock Disposition 2020-11-16 6,353 $44.33 274,211 No 4 F Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 F Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2020-11-16 10,000 $0.00 10,000 $1.05
Common Stock Restricted Stock Units Disposition 2020-11-16 12,813 $0.00 12,813 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
18,282 2020-05-19 2029-09-24 No 4 M Direct
179,375 No 4 M Direct
  1. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020.
  2. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
  3. Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 12,813 shares of Common Stock underlying the Reporting Person's RSUs.
  4. The RSUs vest over approximately four years with a vesting commencement date of May 16, 2020 and have no expiration date. 6.25% of the RSUs vested on August 16, 2020 and November 16, 2020 and an additional 6.25% will vest in quarterly installments on the 16th day of each February, May, August and November thereafter, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date.